Comparing the Effect of Transcranial Direct Current Stimulation (tDCS) With Cognitive-Behavioral therapy (CBT) Interventions on the stress and anxiety and depression and relapse in abstinent methamphetamine-dependent subjects in Farabi Hospital.

开始日期2022-07-23

申办/合作机构

Kermanshah University of Medical Sciences

NCT03825536 / Completed临床4期IIT

Short-term Effects of Methamphetamine Exposure on Residual Viral Transcription During Treated HIV Disease

The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation. A challenge in achieving worldwide HIV eradication is targeting specific marginalized populations who are most likely to benefit from an HIV cure but possess poorer immune responses. For this study, HIV+ infected ART-suppressed individuals with no prior history of MA use disorder will be administered oral methamphetamine (the maximum FDA approved daily dose for the treatment of childhood obesity) to determine the effects of short-term MA exposure on residual virus production, gene expression, and inflammation. Measures of MA exposure in urine and serum will then be associated with residual virus production, gene expression, cell surface immune marker protein expression, and systemic markers of inflammation. The clinical trial data will generate advanced gene expression and immunologic data to identify potential novel targets for reversing HIV latency, reducing inflammation, and personalizing future therapies in HIV+ individuals who use MA.

开始日期2021-01-01

申办/合作机构

The University of California, San Francisco

[+1]

100 项与盐酸去氧麻黄碱相关的临床结果

登录后查看更多信息

100 项与盐酸去氧麻黄碱相关的转化医学

登录后查看更多信息

100 项与盐酸去氧麻黄碱相关的专利（医药）

登录后查看更多信息

109

项与盐酸去氧麻黄碱相关的文献（医药）

2025-01-01·DRUG AND ALCOHOL DEPENDENCE

Effects of the kappa-opioid receptor antagonist nor-binaltorphimine on methamphetamine-vs-food choice in male rhesus monkeys

Article

作者: Rice, Kenner C ; Banks, Matthew L

BACKGROUND:

Kappa-opioid receptors (KOR) are hypothesized to be involved in mediating ongoing methamphetamine self-administration. Previous rat studies have demonstrated that treatment with the KOR antagonist nor-binaltorphimine (nor-BNI) decreases methamphetamine self-administration. However, KOR antagonist effects on methamphetamine self-administration in nonhuman primates are unknown.

METHODS:

Operant behavior was maintained under a concurrent schedule of banana-flavored pellets (fixed-ratio 100 schedule) and intravenous methamphetamine injections (0-0.32mg/kg/injection, fixed-ratio 10 schedule) in male rhesus monkeys (n=3). Methamphetamine choice dose-effect functions were determined 7 days before and for up to 28 days following 10mg/kg, intramuscular nor-BNI treatment.

RESULTS:

Under continuous saline treatment conditions, methamphetamine-maintained a dose-dependent increase in choice over the alternative food reinforcer. 10mg/kg nor-BNI failed to attenuate methamphetamine choice and trended towards increased methamphetamine choice. Methamphetamine choice returned to pre-nor-BNI treatment levels by 21 or 28 days in all 3 monkeys.

CONCLUSIONS:

The present results do not support the hypothesis that the KOR/dynorphin system robustly modulates methamphetamine self-administration and that KOR antagonists should be considered as methamphetamine use disorder pharmacotherapies. In contrast, these results suggest KOR antagonism may increase methamphetamine reinforcement through blockade of methamphetamine-induced dynorphin release and consequent feedback inhibition.

2025-01-01·EXPERIMENTAL BRAIN RESEARCH

Theta and gamma modulation in the nucleus accumbens as drivers of neurophysiological responses to acute methamphetamine sensitization in mice

Article

作者: Cheaha, Dania ; Samerphob, Nifareeda ; Wongveerakul, Pongpanot ; Kumarnsit, Ekkasit

Methamphetamine (METH) has well-documented long-term effects on the brain, including increased psychomotor activity and behavioral sensitization. However, its immediate effects on the brain's reward system following acute exposure, which may contribute to the development of addiction, are less understood. This study aimed to investigate the effects of acute METH on brain oscillations in the nucleus accumbens of C57BL/6 mice. Mice in the METH group received 5 mg/kg of METH for 5 days during the conditioning phase, followed by an 8-day abstinence period. Afterward, they underwent a 6-minute tail suspension test and were given a 1 mg/kg METH challenge. Local field potential (LFP) data were analyzed for percent total power, mean frequency indices, and phase-amplitude coupling (PAC) to assess the neural effects of METH exposure across these phases. A reduction in theta power was observed across the conditioning, abstinence, and challenge phases of METH exposure. The subsequent METH challenge enhanced gamma oscillations, and PAC analysis revealed a consistent theta-gamma coupling index during both the METH administration and challenge phases. It highlights the sensitivity of the reward system to intense, short-term drug exposure, providing new insights into how acute neural stimulation may contribute to the development of addictive behaviors, reinforcing the brain's vulnerability to drug-induced changes in neural circuitry.

2024-12-01·HERZ

Methamphetamine-induced cardiotoxicity: in search of protective transcriptional mechanisms

Review

作者: Meyer, Thomas ; Annawald, Kristin ; Streckfuss-Bömeke, Katrin

Abstract:

Crystalline methamphetamine hydrochloride is an illegal drug with a high addictive potential, better known by its colloquial name “ice” or “crystal meth”. The abuse of this drug has led to significant health problems worldwide. Like other amphetamine-type stimulants, chronic consumption of methamphetamine leads to direct toxic effects on the central nervous system, causing cognitive impairment, depressive behavior, and other severe neurological or psychiatric symptoms. Besides its neurotoxicity, the drug exhibits numerous deleterious effects on the cardiovascular system, including hypertension, accelerated atherosclerosis, vasospasm-induced acute coronary syndromes, sudden cardiac death, and dilated cardiomyopathy with congestive heart failure and left ventricular dysfunction. The excessive release of catecholamines upon methamphetamine exposure causes vasoconstriction and vasospasm, which ultimately lead to hypertension, tachycardia, endothelial dysfunction, and cardiotoxicity. While numerous studies have focused on transcription factors expressed in the brain that cause the neurotoxic effects of the drug, much less is known about transcription factors involved in the development of methamphetamine-induced heart failure. In this article, we provide an overview of the Janus kinase–signal transducer and activator of transcription 3 (JAK–STAT3) pathway involved in ischemia/reperfusion injury in the myocardium, which may be activated by the vasospasm-inducing action of the drug. However, much more work is needed to decipher the precise role of STAT protein family members, including the potentially cardioprotective STAT3, in the pathogenesis of methamphetamine-induced cardiotoxicity.

项与盐酸去氧麻黄碱相关的新闻（医药）

2023-03-31

·drugs

ADHD Med Prescriptions Spiked Early in Pandemic

FRIDAY, March 31, 2023 -- Prescriptions for attention deficit hyperactivity disorder (ADHD) medications spiked during the COVID-19 pandemic, a new government report shows. The trend may reflect both greater awareness among adults of ADHD symptoms and increased stress driving people to get the care they need. “This report shows there is this growing population of adults who have been diagnosed with ADHD, and there is need for support for this population,” lead study author Melissa Danielson , a statistician with the U.S. Centers for Disease Control and Prevention, told NBC News . Prescriptions for ADHD have been increasing since 2016, according to the CDC researchers, who used insurance data on prescription medication for that year through 2021 in people ages 5 to 64. The study, published March 31 in the CDC publication Morbidity and Mortality Weekly Report, noted that prescriptions filled for stimulant medication increased to 4.1% in 2021 from 3.6% in 2016 among those enrolled in employer-sponsored insurance. The increase was even more pronounced in certain age groups: Among adolescent and adult females ages 15 to 44 and males ages 25 to 44, prescriptions grew 10% from 2020 to 2021. They also rose nearly 20% among females in an even narrower age range, 20 to 24. The medications tracked in the analysis were stimulants sold under the brands Dexedrine and Adderall, methamphetamine under the brand Desoxyn , and methylphenidate , known as Ritalin . A few factors may play into the increases, including greater awareness about symptoms, particularly symptom differences in women; an increase in all mental health diagnoses during the pandemic, and increased access because of changes in how ADHD is diagnosed, NBC News reported. Telehealth may also have played a role. “People tend to seek out diagnoses during times of stress and crisis, and we have anecdotal evidence that there was a significant increase in people seeking diagnoses during the pandemic,” Joshua Langberg , an ADHD specialist and director of the Center for Youth Social Emotional Wellness at Rutgers University in New Jersey, told NBC News. The changes in how ADHD is diagnosed were due to a 2013 update in guidelines in the Diagnostic and Statistical Manual of Mental Disorders. Among the changes included are ADHD symptoms starting later, at age 12 rather than at age 7, to be eligible for a diagnosis, NBC News reported. Adults also need to have fewer symptoms to qualify. Generally, symptoms of ADHD are inattention, hyperactivity-impulsivity, not following through on instructions, not paying close attention to details, losing things and talking excessively. Mental health providers also saw patients via telehealth during the pandemic and prescribed stimulants without seeing patients in person, NBC News reported. “That increased access allowed some people who had flown under the radar, or who said they were doing well enough, to get help,” J. Russell Ramsay , director of the Adult ADHD Treatment and Research Program at the University of Pennsylvania’s Perelman School of Medicine, told NBC News . Ramsay said there has been both over- and underdiagnosis of the disorder. “A comprehensive evaluation for ADHD is time-consuming, can be costly and it involves not just assessing for ADHD, but other things that can lead to concentration issues such as anxiety, depression and lack of sleep,” he explained. Providers sometimes have limited resources to take this into account, and some telehealth companies and pharmacies are being investigated for potentially overprescribing ADHD medication, NBC News reported. “Because ADHD occurs with other mental health disorders half the time, you have to make sure one of those is not causing symptoms of ADHD,” Dr. Lenard Adler , director of the Adult ADHD Program at NYU Langone, told NBC News . “You have to take a careful history.” Sources Morbidity and Mortality Weekly Report , March 31, 2023 NBC News Posted March 2023 Further Support and Information on COVID-19 COVID-19: Prevention & Investigational Treatments COVID-19 Support Group Coronavirus Disease Guide

2023-03-16

·PRNewswire

Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder

Myosin Therapeutics Inc., a biotechnology company leveraging its innovative platform technology to identify new molecular entities capable of selectively targeting nanomotor proteins, announced today that it supplemented its National Institutes of Health (NIH) funding with a seed funding round to advance the company's lead programs on glioblastoma and stimulant use disorder. Myosin Therapeutics, Inc. (the "Company") is developing its lead compound, MT-125, to treat glioblastoma, which is a highly aggressive form of brain cancer with a 95% fatality rate and limited treatment options available. In early models, MT-125 has shown that it can simultaneously arrest cancer cell division and migration, and therefore could be a first-in-class therapy. The Company believes that this funding should allow it to reach IND filing for MT-125. Stimulant use disorder, which includes dependence on drugs such as methamphetamine and cocaine, affects millions of people worldwide, is associated with significant morbidity and mortality, and has no FDA-approved treatments. The Company believes that this capital infusion along with existing funding from the National Institute of Health should provide the funding needed to advance Myosin Therapeutics' other lead compound, MT-110, for stimulant use disorders through Phase 1 clinical trials. "We are excited to receive this funding, which will allow us to rapidly advance our first-in-class treatments for glioblastoma and stimulant use disorder, two devastating conditions that lack effective treatments," said Dr. Courtney Miller, co-founder of Myosin Therapeutics. "Our platform for targeting the largely untapped families of nanomotor proteins represents a unique and promising strategy for oncology, in particular." The seed funding round was led by Mint12 Pharma, LLC, with participation from the University of Florida Ventures, DeepWork Capital, and the Florida Opportunity Fund. Mint12 Pharma's Managing Partner, Dave Adams, said, "We are thrilled to partner with Myosin Therapeutics to develop innovative therapies for these two conditions that currently lack effective treatment. Myosin's nanomotor platform has tremendous potential and we look forward to seeing the company's progress in the coming years." About Myosin Therapeutics. Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Herbert Wertheim UF Scripps Institute (formerly Scripps Research, Florida) focused on develop therapies for central nervous system and oncology indications with a platform for targeting molecular nanomotor proteins. The company's lead programs for glioblastoma and stimulant use disorder target myosin motor proteins, which play a critical role in a wide range of cellular processes. Myosin Therapeutics was founded in 2020 by Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka. To learn more about the company, please visit www.myosintherapeutics.com. Mint12 Pharma invests in new patented core pharmaceutical and biotech technologies that have the potential to address fast growing and underserved markets with no current FDA approved therapies by providing financing, placing new executive management to support existing scientific leadership, and governance oversight. Mint12 Pharma provides Seed and Series A financing to companies and is led by an experienced team of Pharma/Biotech operators and investing professionals. SOURCE Myosin Therapeutics Inc.

2022-03-03

·SYNAPSE

BayMark Announces Acquisition Of Residential Treatment Centers In Arizona And Colorado

BayMark Health Services expands its residential footprint in the West with the acquisition of Pathfinders Recovery Center and Emerald Isle Health and Recovery. LEWISVILLE, Texas, March 4, 2022 /PRNewswire-PRWeb/ -- BayMark Health Services has announced the acquisition of three residential and outpatient substance use treatment programs located in the Phoenix, AZ and Denver, CO metropolitan areas. Pathfinders Recovery Center has locations in Scottsdale, AZ and Aurora, CO while Emerald Isle Health and Recovery is located in the Surprise, AZ area. The Pathfinders and Emerald Isle programs offer patient-centered services in comfortable, private facilities allowing each patient to focus on their recovery with minimal distraction. With this exciting acquisition, BayMark now operates 13 residential treatment programs within 7 states. Pathfinders and Emerald Isle offer a broad continuum of care including residential detox, inpatient care, dual diagnosis programs, partial hospitalization programs (PHP), intensive outpatient programs (IOP) and transitional housing for both substance use and mental health disorders. The substance use programs offer individuals a pathway to recovery from alcohol and drug addictions including opioids, benzodiazepines, cocaine, methamphetamine, prescription medications, fentanyl and other illicit substances. Each treatment center also offers mental health services including psychiatric evaluations, individual and family therapy, medication management and other complementary behavioral health services. No matter where a patient may be in their recovery process, Pathfinders and Emerald Isle serves as a source of healing, hope and education for individuals living with behavioral health disorders. "As BayMark continues to broaden and expand our continuum of care, our goal is to seek out organizations with a patient-first approach to substance use disorder treatment and co-occurring disorders," noted Mike Saul, BayMark Executive Vice-President. "The Pathfinders and Emerald Isle programs combine effective behavioral therapies and medical interventions in a state-of-the-art residential environment. This approach provides patients, and their families, a path to long-term recovery that works." BayMark operates other modalities of substance use disorder treatment in the Denver and Phoenix areas including traditional Opioid Treatment Programs (OTP) offering methadone or buprenorphine and counseling and outpatient detox programs with case management and aftercare support. The addition of IOP, PHP and residential programming, alongside transitional housing, offers patients the power of choice when determining what treatment option is right for them. The Braff Group, a leading mergers and acquisitions firm, represented Pathfinders Recovery Center and Emerald Isle Health and Recovery in this transaction. For more information or to make a referral, visit PathfindersAZ.com or EmeraldIsleHealthandRecovery.com. About BayMark Health Services: BayMark Health Services provides Substance Use Disorder and Mental Health treatment services to 73,000+ individuals actively participating in treatment each and every day across 397 recovery programs in 36 states and 3 Canadian provinces. The largest provider of Opioid Use Disorder (OUD) services in North America and the leader in comprehensive behavioral health services for SUD's and Behavioral Disorders, BayMark's continuum of care includes medication-assisted treatment (MAT), withdrawal management, PHP, IOP, counseling and other innovative and effective therapies in outpatient, inpatient and residential settings.

并购

100 项与盐酸去氧麻黄碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸去氧麻黄碱	N06BA03	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	AJENAT PHARMACEUTICALS LLC	1943-12-31
抑郁症	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01
发作性睡病	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01
精神分裂症	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2020	N/A	HIV感染	645	No methamphetamine use	鏇廠製夢衊顧窪願壓糧(窪壓網齋餘鏇憲鑰獵窪): P-Value = 1.84	-	2020-01-01
				1-19 days of methamphetamine use
SFN2019	N/A	-	-	Methamphetamine 0.06 mg/kg/infusion	網膚繭餘廠願積願糧餘(餘鏇鹽廠蓋選廠齋繭壓) = 鑰窪壓築鏇憲醖蓋廠鏇膚鹹範艱糧鬱顧蓋顧襯 (鏇蓋築築膚網觸窪糧鹹 ) 更多	-	2019-10-20
				Methamphetamine 0.015 mg/kg/infusion	網膚繭餘廠願積願糧餘(餘鏇鹽廠蓋選廠齋繭壓) = 窪壓鏇齋鹽遞淵範醖網膚鹹範艱糧鬱顧蓋顧襯 (鏇蓋築築膚網觸窪糧鹹 ) 更多
Hawaii Aging with HIV Cardiovascular Study (IAS2019)	N/A	HIV感染	43	never-used	淵顧願構糧顧衊繭積顧(窪簾艱餘夢艱壓選衊膚) = 選築艱簾齋簾膚廠齋艱簾衊餘選餘鬱製繭築餘 (鹽願膚顧鏇鹽廠鹹糧築 )	-	2019-01-01
				recent-users	淵顧願構糧顧衊繭積顧(窪簾艱餘夢艱壓選衊膚) = 糧窪憲鹽網憲選餘醖憲簾衊餘選餘鬱製繭築餘 (鹽願膚顧鏇鹽廠鹹糧築 )
SFN2018	N/A	甲基苯丙胺依赖	-	Methamphetamine 0.3 mg/kg	餘餘鏇壓壓衊簾衊糧築(鬱繭憲壓獵壓糧淵網蓋) = 顧願鬱廠築構淵窪簾願夢膚壓獵繭選鏇廠艱築 (獵鏇襯窪廠觸衊鏇衊齋 )	-	2018-11-03
				Methamphetamine 2.0 mg/kg	餘餘鏇壓壓衊簾衊糧築(鬱繭憲壓獵壓糧淵網蓋) = 鏇夢遞壓窪觸窪鑰鹹醖夢膚壓獵繭選鏇廠艱築 (獵鏇襯窪廠觸衊鏇衊齋 )
NIDA P30DA011041 (IAS2017)	N/A	-	603	PWID using methamphetamine (Ice)	顧願鏇觸鑰襯夢醖鏇醖(艱憲齋願鬱襯製獵壓夢) = 網廠壓醖齋鹽願糧夢膚繭糧構範獵選鑰範膚蓋 (繭構壓壓觸糧鹽製鏇艱 ) 更多	-	2017-01-01
SFN2016	N/A	甲基苯丙胺依赖	-	methamphetamine (Adolescent rats)	壓獵鏇網鏇繭觸壓鹹艱(淵構襯糧蓋艱鏇顧鏇蓋) = 鏇積構衊繭鏇醖廠壓範壓夢鏇簾襯壓顧構獵繭 (夢鹽壓夢襯構鑰繭繭夢 ) 更多	-	2016-11-16
				methamphetamine (Adult rats)	壓獵鏇網鏇繭觸壓鹹艱(淵構襯糧蓋艱鏇顧鏇蓋) = 範鑰廠積餘願獵艱鹹觸壓夢鏇簾襯壓顧構獵繭 (夢鹽壓夢襯構鑰繭繭夢 ) 更多
SFN2015	N/A	甲基苯丙胺依赖	-	Methamphetamine 1.0 mg/kg	積構壓觸範膚糧鬱淵醖(遞糧憲鏇簾願願廠選構) = 鹹顧窪願鑰鏇繭醖顧憲憲築繭鬱積糧構鏇築製 (鑰觸願積鹹廠憲鑰膚蓋 )	-	2015-10-19
				Methamphetamine 2.0 mg/kg	夢獵淵鬱鑰壓艱鬱顧餘(憲願繭繭構選簾衊衊觸) = 鏇網齋醖獵廠憲憲齋觸網構艱餘壓簾齋簾蓋鹽 (糧壓蓋壓窪範蓋簾窪選 )
SFN2015	N/A	甲基苯丙胺滥用	-	Methamphetamine 20 µM	艱壓顧選衊廠醖鹹積觸(膚襯構淵醖願廠選積繭) = Meth decreased K2P channel activity 鏇網壓觸窪範壓醖襯憲 (憲廠鹽獵願艱齋願製願 )	-	2015-10-19
				Methamphetamine 100 µM
SFN2014	N/A	-	-	Muscimol+baclofen	衊醖構憲鏇鑰衊齋窪構(範窪網艱獵窪鑰簾鏇繭) = 觸窪衊艱壓遞壓鏇糧艱蓋鹹選夢齋餘製餘餘繭 (鹽鹽艱艱艱膚窪齋網齋 )	-	2014-11-19
				methamphetamine (Dorsolateral striatum inactivation)	衊醖構憲鏇鑰衊齋窪構(範窪網艱獵窪鑰簾鏇繭) = 艱淵艱鏇網壓蓋選築窪蓋鹹選夢齋餘製餘餘繭 (鹽鹽艱艱艱膚窪齋網齋 )
SFN2014	N/A	-	-	Acute systemic METH	窪壓選範鑰繭築簾淵壓(壓構積淵鑰夢淵壓膚鹽) = METH evoked minor effects on blood pressure 襯餘淵簾築糧廠鹹觸壓 (範願網廠憲獵艱鑰齋齋 )	-	2014-11-19
				Acute ICV METH